

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Dex 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/015,824	12/10/2001	Philippe Collas	50195/002002	7491
21559 7	7590 05/27/2003			
CLARK & ELBING LLP			EXAMINER	
101 FEDERAI BOSTON, MA			TON, THAIAN N	
			ART UNIT	PAPER NUMBER
			1632	
			DATE MAILED: 05/27/2003	7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary    Examiner		Application No.	Applicant(s)				
## Examiner   Thai-An N. Ton   1632    ## An HAILING DATE of this communication app ars on the cover she t with the correspond nee address → Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE f MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  ## THE MAILING TO THIS COMMUNICATION.  ## THE MAILING DATE OF THIS COMMUNICATION.  ## THE MAILING THIS COMMUNICATION.  ## THE MAILING OF THIS COMMUNICATION.  ## T	•						
Period for Reply  A SHORTENED STATULORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILUNG DATE of this communication app ars on the cover she t with th correspond new address Period for Reply  A SHORTENED STATULORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILUNG DATE of THIS COMMUNICATION.  I the proof of from may be available usefur the provisions of 37 CPR 1.136(s). In no event, now war, may a red by set the social provision of the control of the cont	Office Action Summary						
The MALING DATE of this communication app ars on the cover she I with th correspond nce address—Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ∫ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  Entercord for time reby the solidation and of JCRF 1.138(a), in no event, however, may a reply be finely filled.  The MAILING DATE OF THIS COMMUNICATION.  Entercord for time reby the solidation and of JCRF 1.138(a), in no event, however, may a reply be finely filled.  If the period for reply specified above is test in the resultancy period vall again and value of the period for reply specified above. The manning again and leagues St (MONTHS from the railing date of this communication.  Final period for reply is specified above. The manning again and leagues St (MONTHS from the railing date of this communication to block the period of the communication to block the period of the communication.  Final period for the period of the period of the communication to block the period of the communication to block the period of the communication.  This action is FINAL.  2b ∑ This action is f	cmoo nous cumumury						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - series 18. (8) MONTHS from the mailing date of the communication if the period for mply specified across, the maintain statistically priority within the statistical priority of the maintain statistical priority if NAO period for mply specified across, the maintain statistical priority and the statistical priority of the maintain statistical priority if NAO period for mply specified across, the maintain statistical priority and will expire SX (8) MONTHS from the maintain statistical priority if NAO period for mply specified across, the maintain statistical priority and will expire SX (8) MONTHS from the maintain statistical priority if NAO period for mply specified across, the maintain statistical priority and the maintain statistical priority if NAO period for mply specified across, the statistical priority and the maintain statistical priority Any reply received by the Official from the membrane statistical priority and statistical priority Any reply received by the Official statistical priority and statistical priority Any subject to this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 c.D. 11, 453 O.G. 213.  Disposition of Claims  - 4) © Claim(s) 1-20 (s/are pending in the application 4a) Of the above claim(s) is/are vibility in s/are withdrawn from consideration.  - 5) Claim(s) is/are a subject to restriction and/or election requirement.  - Application Papers  - 9) The specification is objected to by the Examiner.  - 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  - Application Papers  - 9) The specification is objected to by the Examiner.  - 11) The proposed drawing correction filed on is/are: a) accepted or b) objected to by the Examiner.  - 12) The proposed drawing sor required to main for forei	The MAILING DATE of this communication app						
Estimates of time may be available under the provides of 3 CFR 1 13(dg.) In no event, however, may a righty to timely field after 5X (6) MONT ISF from the realized act of this communication.  If the product of time may be available under the provides of 5X CFR 1 13(dg.) In no event, however, may a righty to timely be suited to communication.  If the product of the provides account to the provides of the summary of the summ	• •		.,				
2a)  This action is FINAL. 2b)  This action is non-final.  3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parts Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4)  Claim(s)  1-30 is/are pending in the application.  4a) Of the above claim(s)  is/are withdrawn from consideration.  5)  Claim(s)  is/are allowed.  6)  Claim(s)  is/are rejected.  7)  Claim(s)  is/are objected to.  8)  Claim(s)  1-30 are subject to restriction and/or election requirement.  Application Papers  9)  The specification is objected to by the Examiner.  10)  The drawing(s) filed on  is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11)  The proposed drawing correction filed on  is: a) approved by disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12)  The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)  All b)  Some  O  None of:  1.  Certified copies of the priority documents have been received in Application No.  application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14)  Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a)  The translation of the foreign language provisional application has been received.  15)  Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121.  Attachment(s)	<ul> <li>THE MAILING DATE OF THIS COMMUNICATION.</li> <li>Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.</li> <li>If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.</li> <li>Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).</li> <li>Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) ○ Claim(s) 1-30 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are allowed.  7) □ Claim(s) is/are objected to.  8) ○ Claim(s) 1-30 are subject to restriction and/or election requirement.  Application Papers  9) □ The specification is objected to by the Examiner.  10) □ The drawing(s) filled on is/are: a) □ accepted or b) □ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) □ The proposed drawing correction filled on is: a) □ approved b) □ disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) □ The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) □ All b) □ Some * c) □ None of:  1. □ Certified copies of the priority documents have been received.  2. □ Certified copies of the priority documents have been received in Application No  3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  10 □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.	1) Responsive to communication(s) filed on	<u> </u>					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1-30 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-30 are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s) 11 Notice of References Cited (PTO-892) 5 Notice of Draftspersons Patent Drawing Review (PTO-948) 5 Notice of Informal Patent Application (PTO-152) 6 Other:	2a) This action is <b>FINAL</b> . 2b) ⊠ Th	is action is non-final.					
4)							
4a) Of the above claim(s) is/are withdrawn from consideration.  5)	Disposition of Claims						
5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) is/are objected to. 8) Claim(s) is/are objected to restriction and/or election requirement. Application Papers  9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  Notice of Preferences Cited (PTO-892) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:							
6  Claim(s) is/are rejected. 7  Claim(s) is/are objected to. 8  Claim(s) is/are objected to. 8  Claim(s) is/are objected to. 8  Claim(s) is/are objected to by the Examiner.  4  Application Papers 9  The specification is objected to by the Examiner. 10  The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
7)  Claim(s) is/are objected to.  8)  Claim(s) 1-30 are subject to restriction and/or election requirement.  Application Papers  9)  The specification is objected to by the Examiner.  10)  The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) □ The proposed drawing correction filed on is: a) □ approved b) □ disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) □ The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) □ All b) □ Some * c) □ None of:  1. □ Certified copies of the priority documents have been received.  2. □ Certified copies of the priority documents have been received in Application No  3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) □ The translation of the foreign language provisional application has been received.  15) □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) □ Notice of References Cited (PTO-892)  3) □ Information Disclosure Statement(s) (PTO-1449) Paper No(s)	·						
8) Claim(s) 1-30 are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  All Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  6) Other:	<u> </u>						
Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  6) Other:	<u> </u>						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  A) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  6) Other:	· · · · · · · · · · · · · · · · · · ·						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some column is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  A) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	. · · ·	r					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  6) Other:							
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some colonge of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  All Interview Summary (PTO-413) Paper No(s).  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).  6) Other:							
12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)							
Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  6) Other:							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s).  5) Notice of Informal Patent Application (PTO-152)  1) Information Disclosure Statement(s) (PTO-1449) Paper No(s).  6) Other:	12) The oath or declaration is objected to by the Examiner.						
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  5) Notice of Informal Patent Application (PTO-152)  1) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	Priority under 35 U.S.C. §§ 119 and 120						
1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  5) Notice of Informal Patent Application (PTO-152)  1) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  6) Other:	a) All b) Some * c) None of:						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s).  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).  6) Other:	1. Certified copies of the priority documents have been received.						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  6) Other:	2. Certified copies of the priority documents have been received in Application No						
a)  The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:	application from the International Bureau (PCT Rule 17.2(a)).						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)    5) Notice of Informal Patent Application (PTO-152)  6) Other:	Attachment(s)						
	Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal					

Page 2

Application/Control Number: 10/015,824

Art Unit: 1632

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 2, 4, 14-16 and 18-23, drawn to methods of reprogramming a cell comprising incubating a chromatin mass or nucleus from a donor cell with a reprogramming media under conditions that allow the removal of a factor from the chromatin mass or nucleus, or the addition of a factor from the reprogramming media to the chromatin mass or nucleus, and inserting the nucleus or chromatin mass into a recipient cell or cytoplast, cells produced by the method, classified in class 435, subclass 377.
- II. Claims 3, 4, 13 and 17-25, drawn to methods of reprogramming a cell by incubating a permeabilized cell with a reprogramming media under conditions that allow the removal of a factor from the nucleus or chromatin mass, or the addition of a factor from the reprogramming media to the nucleus or chromatin mass and cells produced by the method, classified in class 435, subclass 377.
- III. Claim 5, drawn to a cell that expresses a T-cell receptor or IL-2 and one or more fibroblast-specific proteins, classified in class 435, subclass 325+.
- IV. Claim 6, drawn to a cell that expresses a neurofilament protein and one or more fibroblast-specific proteins, classified in class 435, subclass 325+.
- V. Claim 7, drawn to a cell that expresses that neurofilament protein NF200 and is immortalized, classified in class 435, subclass 325+.
- VI. Claim 8, drawn to a cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast specific proteins, classified in class 435, subclass 325+.
- VII. Claim 9, drawn to a cell that expresses one or more fibroblast-specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies, classified in class 435, subclass 325+.

Art Unit: 1632

- VIII. Claims 10, 11, 14-16, 18-23, 26 and 27, drawn to methods of treating or preventing a disease, disorder or condition in a mammal comprising incubating a nucleus or chromatin mass from a donor cell with a reprogramming media under conditions that allow the removal of a factor from the nucleus or chromatin mass or the addition of a factor from the reprogramming media, inserting the nucleus or chromatin mass into a recipient cell or cytoplast, and administering the resulting reprogrammed cell to a mammal, classified in class 424, subclass 93.1, 93.21.
- IX. Claims 12, 13, 17-27, drawn to methods of treating or preventing a disease, disorder or condition in a mammal comprising incubating a permeabilized cell with a reprogramming media under conditions that allow removal of a factor from the nucleus or chromatin mass of the permeabilized cell or the addition of factor from the reprogramming media to the nucleus or chromatin mass, and administering the resulting reprogrammed cell to a mammal, classified in class 424, subclass 93.1, 93.21.
- X. Claims 28-30, drawn to methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

Invention I and any of Inventions II-VII, IX and X are mutually exclusive and independent. The methods of reprogramming a cell comprising incubating a chromatin mass or nucleus from a donor cell with a reprogramming media under conditions that allow the removal of a factor from the chromatin mass or nucleus, or the addition of a factor from the reprogramming media to the chromatin mass or nucleus, and inserting the nucleus or chromatin mass into a recipient cell or cytoplast of Invention I are not required for the implementation of the methods of reprogramming a cell by incubating a permeabilized cell with a reprogramming

Art Unit: 1632

media under conditions that allow the removal of a factor from the nucleus or chromatin mass, or the addition of a factor from the reprogramming media to the nucleus or chromatin mass of Invention II, the cell that expresses a T-cell receptor or IL-2 and one or more fibroblast specific proteins of Invention III, the cell that expresses a neurofilament protein and one or more fibroblast specific proteins of Invention IV, the cell that expresses that neurofilament protein NF200 and is immortalized of Invention V, the cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast specific proteins of Invention VI, the cell that expresses one or more fibroblast specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the methods requires a separate and materially different protocol.

Inventions I and VIII are related as process of making and process of using the product. The use as claimed cannot be practiced with a materially different product. Since the product is not allowable, restriction is proper between said method of making and method of using. The product claim will be examined along with the elected invention (MPEP § 806.05(i)).

Invention II and any of Inventions III-VIII and X are mutually exclusive and independent. The methods of reprogramming a cell by incubating a permeabilized

Art Unit: 1632

cell with a reprogramming media under conditions that allow the removal of a factor from the nucleus or chromatin mass, or the addition of a factor from the reprogramming media to the nucleus or chromatin mass of Invention II are not required for the cell that expresses a T-cell receptor or IL-2 and one or more fibroblast-specific proteins of Invention III, the cell that expresses a neurofilament protein and one or more fibroblast-specific proteins of Invention IV, the cell that expresses that neurofilament protein NF200 and is immortalized of Invention V, the cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast-specific proteins of Invention VI, the cell that expresses one or more fibroblast-specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention VIII, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the methods requires a separate and materially different protocol.

Inventions II and IX are related as process of making and process of using the product. The use as claimed cannot be practiced with a materially different product. Since the product is not allowable, restriction is proper between said method of making and method of using. The product claim will be examined along with the elected invention (MPEP § 806.05(i)).

Invention III and any of Inventions IV-X are mutually exclusive and independent. The cell that expresses a T-cell receptor or IL-2 and one or more

Art Unit: 1632

fibroblast specific proteins of Invention III is not required for the cell that expresses a neurofilament protein and one or more fibroblast specific proteins of Invention IV, the cell that expresses that neurofilament protein NF200 and is immortalized of Invention V, the cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast specific proteins of Invention VI, the cell that expresses one or more fibroblast specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention VIII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the cells of Inventions III-VII are materially different cells that are not required for implementation of the other.

Invention IV and any of Inventions V-X are mutually exclusive and independent. The cell that expresses a neurofilament protein and one or more fibroblast specific proteins of Invention IV is not required for the cell that expresses that neurofilament protein NF200 and is immortalized of Invention V, the cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast specific proteins of Invention VI, the cell that expresses one or more fibroblast specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention VIII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa.

Art Unit: 1632

Furthermore, each of the cells of Inventions IV-VII are materially different cells that are not required for implementation of the other.

Invention V and any of Inventions VI·X are mutually exclusive and independent. The cell that expresses that neurofilament protein NF200 and is immortalized of Invention V is not required for the cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast specific proteins of Invention VI, the cell that expresses one or more fibroblast specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention VIII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the cells of Inventions V-VII are materially different cells that are not required for implementation of the other.

Invention VI and any of Inventions VII-X are mutually exclusive and independent. The cell that expresses Oct4 or alkaline phosphatase and one or more fibroblast-specific proteins of Invention VI is not required for the cell that expresses one or more fibroblast-specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII, the methods of treatment of Invention VIII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the cells of

Art Unit: 1632

Inventions VI and VII are materially different cells that are not required for implementation of the other.

Invention VII and any of Inventions VIII-X are mutually exclusive and independent. The cell that expresses one or more fibroblast-specific proteins and grows in aggregates, forms colonies, or forms embryoid bodies of Invention VII is not required for the implementation of the methods of treatment of Invention VIII, the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa.

Inventions VIII and either of Inventions IX or X are mutually exclusive and independent. The methods of treatment of Invention VIII are not required for the implementation of the methods of treatment of Invention IX, and the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the methods requires a separate and materially different protocol.

Inventions IX and X are mutually exclusive and independent methods. The methods of treatment of Invention IX are not required for the implementation of the methods for measuring endogenous alkaline phosphatase protein in a cell, nucleus, chromatin mass, or *in vitro* sample of Invention X, and vice versa. Furthermore, each of the methods requires a separate and materially different protocol.

Art Unit: 1632

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

DEBORAH CROUCH PRIMARY EXAMINER GROUP 1800/630

Art Unit: 1632

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thái-An N. Ton whose telephone number is (703) 305-1019. The examiner can normally be reached on Monday through Friday from 8:00 to 5:00 (Eastern Standard Time), with alternating Fridays off. Should the examiner be unavailable, inquiries should be directed to Deborah Reynolds, Supervisory Primary Examiner of Art Unit 1632, at (703) 305-4051. Any administrative or procedural questions should be directed to William Phillips, Patent Analyst, at (703) 305-3482. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 872-9306.

TNT

Thái-An N. Ton Patent Examiner Group 1632